Targeted Antibody-Drug combo shows promise for Hard-to-Treat lung cancer
NCT ID NCT07662473
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the drug trastuzumab deruxtecan (T-DXd) in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has high levels of the HER2 protein. Participants receive T-DXd by IV every three weeks. The study measures how long the cancer stays under control and overall survival. It enrolls about 30 adults whose cancer has worsened after at least one prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (T-DXd)
What this could lead to
If successful, this could offer a new treatment option for people with advanced lung cancer that overproduces HER2 protein.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply broadly. The drug can cause serious side effects like lung inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••